SCHEMBL23218700

SCHEMBL23218700

CCOC(=O)Cc1ccc(CC)cc1OCc1c(C)oc2ccc(-c3cccc(CN)c3)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 9/20 0.46
F11 P03951 3/20 0.41
TPSB2 P20231 2/20 0.41
KLKB1 P03952 2/20 0.41
PLG P00747 1/20 0.41
PLAU P00749 1/20 0.41
F7 P08709 1/20 0.41
P2RX3 P56373 1/20 0.35
MAPT P10636 2/20 0.34
ANO1 Q5XXA6 1/20 0.34
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
RXRG P48443 1/20 0.34
ACLY P53396 1/20 0.34
LMNA P02545 1/20 0.33
MEN1 O00255 1/20 0.33
GAA P10253 1/20 0.33
KMT2A Q03164 1/20 0.33
DPP4 P27487 1/20 0.33
SYK P43405 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853195 1.00 CFD (0.46) CFDF11TPSB2KLKB1PLG
SCHEMBL23218387 0.92 CFD (0.45) CFDF11TPSB2KLKB1PLG
SCHEMBL29852379 0.92 CFD (0.45) CFDF11TPSB2KLKB1PLG
SCHEMBL29591609 0.92 CFD (0.52) CFDF11TPSB2KLKB1PLG
SCHEMBL23218042 0.92 CFD (0.52) CFDF11TPSB2KLKB1PLG
SCHEMBL23218574 0.91 CFD (0.45) CFDF11TPSB2KLKB1PLG
SCHEMBL29852604 0.91 CFD (0.45) CFDF11TPSB2KLKB1PLG
SCHEMBL23218837 0.91 CFD (0.53) CFDF11TPSB2KLKB1PLG
SCHEMBL29852712 0.91 CFD (0.53) CFDF11TPSB2KLKB1PLG
SCHEMBL23218533 0.90 CFD (0.43) CFDF11TPSB2KLKB1PLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885F11 24/4885TPSB2 419/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885F11 14/4885TPSB2 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.